SCHEMBL1060507

SCHEMBL1060507

c1ccc(Nc2ncnc3nc[nH]c23)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 3/20 0.72
▸ RAB9A P51151 6/20 0.69
▸ HTT P42858 4/20 0.69
▸ SMN1; SMN2 Q16637 3/20 0.69
▸ MAPK1 P28482 3/20 0.69
▸ BRAF P15056 3/20 0.69
▸ TOP2A P11388 2/20 0.69
▸ HSD17B10 Q99714 2/20 0.69
▸ TSHR P16473 2/20 0.69
▸ GFER P55789 1/20 0.69
▸ NPC1 O15118 5/20 0.69
▸ MEN1 O00255 2/20 0.69
▸ MAPT P10636 2/20 0.69
▸ HPGD P15428 2/20 0.69
▸ KMT2A Q03164 2/20 0.69
▸ TP53 P04637 1/20 0.69
▸ LMNA P02545 2/20 0.64
▸ ROCK1 Q13464 1/20 0.63
▸ CYP1A2 P05177 1/20 0.61
▸ CYP2D6 P10635 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29501954 0.85 LMNA (0.60) MKNK1RAB9AHTTSMN1; SMN2MAPK1
SCHEMBL4923804 0.84 MKNK1 (0.73) MKNK1RAB9AHTTSMN1; SMN2MAPK1
SCHEMBL4921641 0.84 MKNK1 (0.73) MKNK1RAB9AHTTSMN1; SMN2MAPK1
SCHEMBL4926098 0.84 MKNK1 (0.73) MKNK1RAB9AHTTSMN1; SMN2MAPK1
SCHEMBL4922517 0.84 MKNK1 (1.00) MKNK1RAB9AHTTSMN1; SMN2MAPK1
SCHEMBL17009458 0.83 RAB9A (0.61) MKNK1RAB9AHTTSMN1; SMN2MAPK1
SCHEMBL4917996 0.82 SMN1; SMN2 (0.71) MKNK1RAB9AHTTSMN1; SMN2MAPK1
SCHEMBL4913665 0.82 SMN1; SMN2 (0.71) MKNK1RAB9AHTTSMN1; SMN2MAPK1
SCHEMBL4923320 0.82 SMN1; SMN2 (0.71) MKNK1RAB9AHTTSMN1; SMN2MAPK1
SCHEMBL4922640 0.82 SMN1; SMN2 (1.00) MKNK1RAB9AHTTSMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117597021-A Method for high-volume production of polyphenols from red lettuce and use thereof 新格诺康植物技术公司 2024-02-23 — — CN claimed
CN-116076620-A Application of polyphenol lettuce in animal feed 浙江迦美善植物科技有限公司 2023-05-09 — — CN claimed
CN-110882290-A Application of extract of rhinacanthus nasutus callus, method for inducing and proliferating rhinacanthus nasutus callus and culture medium 大江生医股份有限公司 2020-03-17 — — CN claimed
CN-109907317-A For adjusting the dendrobium candidum extract and preparation method thereof of skin metabolism 大江生医股份有限公司 2019-06-21 — — CN claimed
CN-104447746-A Compound for activating AMPK and application thereof HUAAN MEDICAL CO LTD 2015-03-25 — — CN claimed
US-20140303112-A1 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) ENERGENESIS BIOMEDICAL CO., LTD (TW) 2014-10-09 — — US claimed
CN-102037157-B Adhesion promotion of metal to laminate with a multi-functional compound ENTHONE 2014-05-28 — — CN claimed
EP-2173173-B1 SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES UNIV PALACKEHO (CZ) 2013-07-24 — — EP claimed
EP-2546387-A1 Adhesion promotion of metal to laminate with a multi-functional compound Enthone, Inc. (US) 2013-01-16 — — EP claimed
EP-2274460-B1 ADHESION PROMOTION OF METAL TO LAMINATE WITH A MULTI-FUNCTIONAL COMPOUND ENTHONE (US) 2012-10-10 — — EP claimed
CN-102037157-A Adhesion promotion of metal to laminate with a multi-functional compound ENTHONE 2011-04-27 — — CN claimed
EP-2274460-A1 ADHESION PROMOTION OF METAL TO LAMINATE WITH A MULTI-FUNCTIONAL COMPOUND HAFTFORDERUNG VON METALL ZU LAMINATEN MIT EINER MULTIFUNKTIONELLEN Enthone, Inc. (US) 2011-01-19 — — EP claimed
US-20100190806-A1 SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2010-07-29 — — US claimed
EP-2173173-A2 SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES Univerzita palackeho V Olomouci (CZ) 2010-04-14 — — EP claimed
WO-2009117734-A1 ADHESION PROMOTION OF METAL TO LAMINATE WITH A MULTI-FUNCTIONAL COMPOUND HAFTFORDERUNG VON METALL ZU LAMINATEN MIT EINER MULTIFUNKTIONELLEN ENTHONE INC. (US) 2009-09-24 — — WO claimed
WO-2009003428-A2 SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2009-01-08 — — WO claimed
US-20050043328-A1 Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds USTAV EPERIMENTALNI BOTANIKY AKADEMI VED CESKE REPUBILIKY (CZ) 2005-02-24 — — US claimed
CN-1556808-A Based on N6Heterocyclic compounds of substituted adenine, process for their preparation, their use for the preparation of medicaments, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds �ݿ˹��͹���������ʵ��ֲ��ѧ�� 2004-12-22 — — CN claimed
EP-1419157-A2 HETEROCYCLIC COMPOUND BASED ON N sp 6 /sp −SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) 2004-05-19 — — EP claimed
WO-2003040144-A2 HETEROCYCLIC COMPOUND BASED ON N6-SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) 2003-05-15 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140303112-A1 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) PRKAG2, PRKAB2, PRKAG1 MKNK1 233/4885RAB9A 2154/4885HTT 3291/4885
US-20050043328-A1 Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds ATIC, UMPS, CCNB1 MKNK1 1920/4885RAB9A 1756/4885HTT 1133/4885
US-20100190806-A1 SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES DPYD, XDH, APRT MKNK1 3750/4885RAB9A 3935/4885HTT 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback